An overview of Merkel cells, Merkel cell carcinoma, symptoms, and causes.
Learn More →The diagnosis of MCC is made with a skin biopsy, which is examined under the microscope.
Learn More →There are multiple treatments used for MCC, and treatment is generally based on stage of the disease.
Learn More →Disease recurrence and survival are two critical measures of prognosis.
Learn More →Explore resources about Merkel cell carcinoma, including frequently asked questions and our list of verified specialists.
Learn More →Aim: The aim of this article was to provide worldwide, population-based incidence rates for Merkel cell carcinoma (MCC). Methods: We included 11,576 cases from 20 countries for time trend analyses (1990e2007) and 11,028 cases (2.5 billion person-years) from 21 countries for the period 2003e2007 extr...
Read more →BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human antiâ€...
Read more →The University of Washington Newsletter recently published the story of Robert Yolles-- a husband whose ultimate goal was to help his wife, Monica, find the best possible doctors and treatments for her Merkel cell carcinoma. Through his search, he found Dr. Paul Nghiem. To this day, Yolles remains c...
Read more →PURPOSE: Patients presenting with nodal Merkel cell carcinoma without an identifiable (unknown) primary lesion (MCC-UP) are nearly twice as likely to survive compared to similarly staged patients with known primary lesions (MCC-KP). The basis of this previously reported finding is unclear. EXPERIMEN...
Read more →Merkel cell carcinoma (MCC) is a rare (~2,000 US cases/year) but aggressive neuroendocrine tumor of the skin. For advanced MCC, cytotoxic chemotherapy only infrequently (1 year) suggesting a great need for improved therapeutic options. In 2008, the Merkel cell polyomavirus (MCPyV) was discovered and...
Read more →Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations af...
Read more →Dear friends of Merkel cell carcinoma research, During this time of giving and celebrations, I want to let you know how appreciative our Merkel Team is of your support. This year was one of many exciting milestones that I am thrilled to share with you.  We have written an annual update lette...
Read more →Authorization for BAVENCIO® (avelumab) as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC) has been granted in several locations worldwide. Updates on avelumab approvals: United States --- March 23, 2017 Switzerland --- September 5, 2017 E...
Read more →Background: Merkel cell carcinoma (MCC) incidence rates are rising and strongly age-associated, relevant for an aging population. Objective: Determine MCC incidence in the United States and project incident cases through the year 2025. Methods: Registry data were obtained from the SEER-18 database, ...
Read more →On October 27, 2017, Laura A. Stokowski, of Medscape, released the details from an interview with Dr. Paul Nghiem regarding Merkel cell carcinoma and its defining characteristics, proper management, and recent advances in treatment options. Use of the "AEIOU" characteristics can help in identifying...
Read more →The authoritative source on Merkel cell carcinoma.
Last updated:
September 13, 2019
Created in partnership with:
Seattle Multidisciplinary MCC Team, University of Washington MCC Research, Fred Hutchinson Cancer Research Center, and the Seattle Cancer Care Alliance/Skin Cancer